Exicure, Inc.
XCUR
Rank in Stocks
#30127
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical... Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Share Price
$0.8903
Last synced: 2026-11-09
Market Cap
$5.83M
Change (1 day)
-6.26%
Change (1 year)
-75.61%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Exicure, Inc. (XCUR)
Category
Healthcare
Operating Margin for Exicure, Inc. (XCUR)
Operating Margin as of November 2026 TTM: 0.00%
According to Exicure, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Exicure, Inc. from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -2,446.40% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -6.35% | -100.05% |
| 2021 | 12,950.10% | -8,558.04% |
| 2020 | -153.11% | -92.54% |
| 2019 | -2,053.78% | -88.89% |
| 2018 | -18,490.68% | 17,168.10% |
| 2017 | -107.08% | -93.14% |
| 2016 | -1,560.04% | 183.43% |
| 2015 | -550.42% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Exicure, Inc.'s operating margin
What was Exicure, Inc.'s operating margin in 2025?
In 2025, Exicure, Inc.'s operating margin was 0.00%, compared with -2,446.40% in 2024.
How has Exicure, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Exicure, Inc.'s operating margin was highest in 2021 (12,950.10%) and lowest in 2024 (-2,446.40%).
How does Exicure, Inc.'s operating margin compare with similar companies?
Exicure, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.